IMRX
Immuneering Corp
NASDAQ · Healthcare · Biotechnology · US
$3.75
−6.84%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-39.4%
Return on equity
-36.4%
Return on assets
—
Return on invested capital
0.00x
Asset turnover
-$51.7B
Cash from operations
$2.25
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026